Search

Your search keyword '"Schoen, Robert E."' showing total 1,488 results

Search Constraints

Start Over You searched for: Author "Schoen, Robert E." Remove constraint Author: "Schoen, Robert E." Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
1,488 results on '"Schoen, Robert E."'

Search Results

2. Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk

4. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

5. Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk.

7. Prospective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer

8. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations

9. Probing the diabetes and colorectal cancer relationship using gene – environment interaction analyses

10. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

12. Body size and risk of colorectal cancer molecular defined subtypes and pathways: Mendelian randomization analyses

13. Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases

14. Elucidating the Risk of Colorectal Cancer for Variants in Hereditary Colorectal Cancer Genes

15. Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures

17. Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention.

18. Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer

19. Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer

20. Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention

21. Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma

22. Supplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma

23. Supplementary Methods S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma

25. Assessing aneuploidy with repetitive element sequencing

26. Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects

27. Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer

28. Fine-mapping analysis including over 254 000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

35. Effectiveness of Colonoscopy Screening vs Sigmoidoscopy Screening in Colorectal Cancer

36. Relationship of prediagnostic body mass index with survival after colorectal cancer: Stage‐specific associations

37. Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting

38. Corrigendum: genome-wide association study of colorectal cancer identifies six new susceptibility loci.

39. Erratum: Corrigendum: Genome-wide association study of colorectal cancer identifies six new susceptibility loci

40. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer

41. Genome-wide association study of colorectal cancer identifies six new susceptibility loci.

44. UNSEG: unsupervised segmentation of cells and their nuclei in complex tissue samples

46. Supplemental Table 4 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

47. Supplemental Table 6 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

48. Supplemental Table 7 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

49. Supplemental Figure 3 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

50. Supplemental Table 2 from Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas

Catalog

Books, media, physical & digital resources